AAVnerGene Unveils High-Yield AAVone®2.1 Platform
ROCKVILLE, Md. – May 8, 2026 AAVnerGene Inc. announced the launch of AAVone®2.1, the next-generation evolution of its proprietary...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ROCKVILLE, Md. – May 8, 2026 AAVnerGene Inc. announced the launch of AAVone®2.1, the next-generation evolution of its proprietary...
YOKNEAM, Israel – May 8, 2026 Lumenis announced that its groundbreaking hair restoration platform FoLix™ has received the Hair...
LONDON, UK – January 7, 2026 — iSMART Developments Ltd., a UK-based innovator in LED light-based skincare, aesthetics, and...
